Topical Ruxolitinib Found Safe, Effective in 52-Week AD Study The FDA has extended the review period for the agent by 3 months to September 2021. If approved, it would become first topical JAK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results